Can you provide a SOAP note with appropriate CPT (Current Procedural Terminology) and ICD‑10 (International Classification of Diseases, Tenth Revision) codes for a 40‑year‑old female returning for a 2‑month follow‑up for hypertension and weight management, who is non‑compliant with amlodipine 5 mg and losartan‑potassium‑hydrochlorothiazide 100 mg/25 mg, reports ineffective medication, has eczema rash on bilateral upper extremities, and bilateral heel pain?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

SOAP Note with CPT and ICD-10 Codes

Subjective

40-year-old female presents for 2-month follow-up of hypertension and weight management. Reports medication non-compliance with current antihypertensive regimen (amlodipine 5 mg daily and losartan-hydrochlorothiazide 100-25 mg daily), stating "I forget." Patient reports current weight management medication (lomira) is ineffective. New complaints include eczematous rash on bilateral upper extremities and bilateral heel pain.

Objective

  • Blood pressure: [document actual BP reading]
  • Weight: [document actual weight and BMI]
  • Skin exam: Eczematous rash noted on bilateral upper extremities
  • Musculoskeletal: Bilateral heel tenderness on palpation

Assessment

1. Uncontrolled hypertension with medication non-adherence

  • ICD-10: I10 (Essential hypertension)
  • ICD-10: Z91.14 (Patient's intentional underdosing of medication regimen due to financial hardship) or Z91.120 (Patient's intentional underdosing of medication regimen for other reason)

2. Overweight/Obesity (document specific BMI)

  • ICD-10: E66.9 (Obesity, unspecified) if BMI ≥30
  • ICD-10: E66.01 (Morbid obesity due to excess calories) if BMI ≥40 or BMI ≥35 with comorbidity
  • ICD-10: Z68.__ (Body mass index [BMI]) - use specific code based on actual BMI

3. Eczematous dermatitis, likely drug-induced

  • ICD-10: L30.9 (Dermatitis, unspecified)
  • ICD-10: T46.5X5A (Adverse effect of other antihypertensive drugs, initial encounter) - ARBs/ACE inhibitors can cause eczematous reactions 1

4. Bilateral plantar fasciitis

  • ICD-10: M72.2 (Plantar fascial fibromatosis)

5. Ineffective weight management pharmacotherapy

  • ICD-10: Z79.899 (Other long term [current] drug therapy)

Plan

Hypertension Management

Address medication non-adherence immediately - this is the primary barrier to BP control 2. The 2025 AHA/ACC guidelines emphasize team-based care and addressing barriers to medication adherence 2.

  • Implement adherence strategies:

    • Simplify regimen to once-daily dosing
    • Consider pill organizers, smartphone reminders, or medication synchronization
    • Assess financial barriers and provide generic alternatives
    • Schedule follow-up in 2-4 weeks (not 2 months) for uncontrolled hypertension 2
  • Medication adjustment: Switch from losartan-hydrochlorothiazide 100-25 mg to losartan-hydrochlorothiazide 50-12.5 mg once daily to reduce pill burden and potentially improve the eczematous rash (lower HCTZ dose may reduce adverse effects) 33. If BP remains uncontrolled after 3 weeks, can uptitrate 33.

  • Continue amlodipine 5 mg daily - this is appropriate dosing and less likely to cause peripheral edema than higher doses. ARBs like losartan can actually reduce amlodipine-induced edema 4.

  • Consider adding amlodipine to 10 mg if BP not controlled after addressing adherence, as combination ARB/CCB therapy is highly effective 45.

Eczematous Rash Management

The eczematous rash is likely caused by the ARB (losartan) or ARB-HCTZ combination - this reaction typically develops 4-30 months after initiation and presents as generalized or localized eczema, often on lower extremities but can affect upper extremities 1.

  • Trial of topical corticosteroid (triamcinolone 0.1% cream twice daily to affected areas for 2 weeks)
  • If rash persists or worsens despite adherence improvement and dose reduction, consider switching from losartan to amlodipine monotherapy or adding a third agent from a different class
  • Oral antihistamines are typically ineffective for this drug-induced eczema 1

Weight Management

For BMI ≥27 with hypertension comorbidity or BMI ≥30, pharmacotherapy is indicated as adjunct to lifestyle modification 6.

  • Discontinue current ineffective weight management medication (lomira)
  • Initiate FDA-approved weight loss medication (specific agent based on contraindications, cost, and patient preference) 6
  • Reassess efficacy at 3 months - if <5% weight loss, discontinue and try alternative agent 6
  • Reinforce diet, exercise, and behavioral modification as foundation 6

Bilateral Heel Pain

  • Conservative management: NSAIDs, heel cushions, stretching exercises, night splints
  • Physical therapy referral if no improvement in 4-6 weeks
  • Consider orthotic evaluation

Follow-up

  • Return in 2-4 weeks for BP recheck and medication adherence assessment (not 2 months - uncontrolled hypertension requires closer monitoring) 2
  • Dermatology referral if rash persists despite treatment
  • Podiatry referral if heel pain not improving with conservative measures

CPT Codes

  • 99214 - Office visit, established patient, moderate complexity (30-39 minutes) - addressing multiple chronic conditions with medication adjustments
  • 99215 - Office visit, established patient, high complexity (40-54 minutes) - if visit duration and complexity support this level

Modifiers: None required for standard office visit


Critical Pitfall: The 2-month follow-up interval is too long for uncontrolled hypertension. The 2025 AHA/ACC guidelines emphasize that frequency of follow-up depends on BP control status 2. Uncontrolled hypertension requires follow-up every 2-4 weeks until BP is at goal, then can extend to monthly or quarterly visits once controlled.

Related Questions

Should I continue Hyzaar (losartan/hydrochlorothiazide) 50 mg daily and amlodipine (calcium‑channel blocker) 2.5 mg twice daily since my blood pressure is 120‑130/69‑80 mm Hg?
What is the ICD‑10 code for shortness of breath?
What is the next step in managing a 47-year-old male with hypertension whose blood pressure remains 150‑160/90‑100 mm Hg despite being on lisinopril 20 mg and losartan combined with hydrochlorothiazide 12.5 mg after amlodipine was discontinued due to peripheral edema?
In a 52-year-old man with hypertension treated with nicardipine 10 mg and telmisartan 40 mg daily for 5 years who now has bilateral pedal edema, more pronounced on the right side, what is the most likely cause and appropriate management?
A 48-year-old woman taking hydrochlorothiazide 12.5 mg daily and nifedipine extended‑release 30 mg daily has blood pressure 140/90 mm Hg and cannot use amlodipine due to peripheral edema; what additional treatment options are appropriate?
What are the first-line treatments for giardiasis and uncomplicated urinary tract infection in an adult?
Should a 72‑year‑old woman with a recent head bump, no dizziness, nausea, vomiting, confusion, loss of balance, or focal neurological deficits, and a prior computed tomography (CT) scan showing only a minute abnormality, have immediate head imaging (CT or X‑ray) now or can imaging be safely deferred until Monday?
Is zoledronic acid (5 mg intravenous infusion annually) an appropriate first‑line therapy for osteoporosis, and what are the renal function criteria, dosing protocol, and monitoring recommendations?
Can febuxostat be used instead of allopurinol in a patient already on febuxostat with a serum uric acid of 9.8 mg/dL and a history of kidney stones?
Is it safe for a patient with type 2 diabetes and uncontrolled hypertension to purchase Ozempic (semaglutide) on the gray market?
What management steps should be taken for a 33-year-old woman with type 2 diabetes mellitus, BMI >34 kg/m², currently on glimepiride, metformin, empagliflozin, and tirzepatide (Mounjaro) titrated to 7.5 mg who continues to have excessive hunger and no weight loss despite stable glycemia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.